The purpose of this study is to assess the efficacy as well as safety and tolerability of a new drug called padsevonil that will be given in one of 3 different doses in addition to your current epilepsy treatment that may consist of 1-3 antiepileptic drugs. The study also aims to see how safe padsevonil is compared to placebo and how well your body can tolerate it.

We are conducting this study to better understand the relationship between access to care, financial stress and health related quality of life among cancer patients in NC who live in rural areas. We will be interviewing 30 rural cancer patients to learn about their cancer experience and we will be reviewing previously completed surveys about their distress and coping behaviors.

Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades despite numerous attempts to augment standard therapies. Multi-targeted receptor tyrosine kinase inhibitors (MTKIs), such as cabozantinib, can target signaling pathways that are known to be altered in osteosarcoma. Several MTKIs including cabozantinib have recently shown clinical evidence of activity in prospective studies for both pediatric and adult patients with advanced osteosarcoma. Furthermore, feasibility of administering MTKIs in combination with cytotoxic chemotherapy has previously been shown in patients with AML, hepatocellular carcinoma, and soft tissue sarcomas. Osteosarcoma is the most common primary bone malignancy of childhood and adolescence. Survival rates for patients with standard risk (localized, resectable primary tumors) and high-risk disease (presence of metastases, unresectable or primary pelvic tumors) are 70% and 20-30%, respectively, and have remained unchanged for several decades

We are working to translate and validate a survey that looks at symptom management and quality of life for patients in Malawi getting palliative care treatment to make sure that the survey is applicable, relatable, and understandable for these patients.

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy in adolescents and young adults (AYAs, age 15-39 years).

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

Some female cancers may be genetic, meaning they are passed down from a parent through DNA (our genetic code or roadmap). In people with certain types of ovarian and uterine cancer, it may be helpful to test their DNA for any errors that can cause cancer. There are lots of important pieces of information to share when someone is diagnosed with cancer, and we are exploring a new way to share information. Patients with certain types of ovarian or uterine cancers will watch a short video that explains what genetic testing is and why it is so important. They will fill out a survey about what they think about the video and if the information is helpful.

No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.

The purpose of this research study is to explore the post-treatment barriers faced by adolescent and young adult (AYA) cancer survivors to therefore adapt the Needs Assessment and Service Bridge (NA-SB) tool produced by the UNC AYA Cancer Program. You are being asked to take part in a research study because you are an adolescent or young adult who has experienced cancer survivorship.

The purpose of this study is to evaluate and compare the survival outcome of patients with first recurrence of GBM undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin chemotherapy or standard of care second line chemotherapy with either lomustine or temozolomide (per best physician's choice and best practice).